Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.
3.

Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma.

Cheung IY, Lo Piccolo MS, Kushner BH, Cheung NK.

J Clin Oncol. 2003 Oct 15;21(20):3853-8.

PMID:
14551304
4.

Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.

Cheung IY, Cheung NK.

Clin Cancer Res. 2001 Jun;7(6):1698-705.

5.

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.

Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, Modak S.

J Clin Oncol. 2012 Sep 10;30(26):3264-70. doi: 10.1200/JCO.2011.41.3807. Epub 2012 Aug 6.

6.

Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.

Cheung NK, Ostrovnaya I, Kuk D, Cheung IY.

J Clin Oncol. 2015 Mar 1;33(7):755-63. doi: 10.1200/JCO.2014.57.6777. Epub 2015 Jan 5.

7.

Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.

Cheung NK, Kushner BH, Cheung IY, Kramer K, Canete A, Gerald W, Bonilla MA, Finn R, Yeh SJ, Larson SM.

J Clin Oncol. 1998 Sep;16(9):3053-60.

PMID:
9738575
8.

N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.

Cheung NK, Kushner BH, LaQuaglia M, Kramer K, Gollamudi S, Heller G, Gerald W, Yeh S, Finn R, Larson SM, Wuest D, Byrnes M, Dantis E, Mora J, Cheung IY, Rosenfield N, Abramson S, O'Reilly RJ.

Med Pediatr Oncol. 2001 Jan;36(1):227-30.

PMID:
11464891
9.

Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.

Cheung NK, Cheung IY, Kramer K, Modak S, Kuk D, Pandit-Taskar N, Chamberlain E, Ostrovnaya I, Kushner BH.

Int J Cancer. 2014 Nov 1;135(9):2199-205. doi: 10.1002/ijc.28851. Epub 2014 Apr 3.

10.

Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.

Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK.

Med Pediatr Oncol. 2001 Jan;36(1):194-6.

PMID:
11464881
11.

GD2 synthase: a new molecular marker for detecting neuroblastoma.

Lo Piccolo MS, Cheung NK, Cheung IY.

Cancer. 2001 Aug 15;92(4):924-31.

PMID:
11550167
12.

Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).

Mora J, Cruz O, Lavarino C, Rios J, Vancells M, Parareda A, Salvador H, Suñol M, Carrasco R, Guillen A, Mañé S, de Torres C.

Clin Transl Oncol. 2015 Jul;17(7):521-9. doi: 10.1007/s12094-014-1273-8. Epub 2015 Jan 17.

PMID:
25596034
13.

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Kramer K, Modak S, Yataghene K, Cheung NK.

Oncoimmunology. 2015 May 22;4(7):e1016704. eCollection 2015 Jul.

14.

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, Roberts SS, Basu EM, Yataghene K, Cheung NK.

Oncotarget. 2016 Jan 26;7(4):4155-66. doi: 10.18632/oncotarget.6393.

15.

Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma.

Cheung IY, Vickers A, Cheung NK.

Int J Cancer. 2006 Jul 1;119(1):152-6.

16.

FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.

Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R.

J Clin Oncol. 2006 Jun 20;24(18):2885-90. Epub 2006 May 8. Erratum in: J Clin Oncol. 2006 Aug 10;24(23):3814.

PMID:
16682723
18.

Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study.

Fukuda M, Miyajima Y, Miyashita Y, Horibe K.

J Pediatr Hematol Oncol. 2001 Jan;23(1):10-3.

PMID:
11196262
19.

Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.

Hoon DS, Kuo CT, Wen S, Wang H, Metelitsa L, Reynolds CP, Seeger RC.

Am J Pathol. 2001 Aug;159(2):493-500.

20.

Supplemental Content

Support Center